ReViral
Signal active
Organization
Contact Information
Overview
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.
About
Industries
Biotechnology, Health Care, Medical, Therapeutics
Founded
2011
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
ReViral headquartered in Europe, operates in the Biotechnology, Health Care, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $7.7B in funding across 64 round(s). With a team of 11-50 employees, ReViral is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - ReViral, raised $1.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
0
Lead Investors
0
Total Funding Amount
$121.0M
Details
3
ReViral has raised a total of $121.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Early Stage Venture | 55.0M | ||
| 2020 | Late Stage Venture | 44.0M | ||
| 2015 | Early Stage Venture | 21.0M |
Investors
ReViral is funded by 30 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| ReViral | - | FUNDING ROUND - ReViral | 21.0M |
| OrbiMed | - | FUNDING ROUND - OrbiMed | 21.0M |
| ReViral | - | FUNDING ROUND - ReViral | 21.0M |
| Brace Pharma | - | FUNDING ROUND - Brace Pharma | 21.0M |
Recent Activity
There is no recent news or activity for this profile.